| 今开：39.64 | 昨收：39.47 |
| 最高：39.94 | 最低：39.64 |
| 涨停价：0.0 | 跌停价：0.0 |
| 总市值：8.835449886E9 |
快而精医药(QGEN)2023-03-13 18:06
$快而精医药(QGEN)$ 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)] Accession Number: 0001015820-23-000012 Act: 34 Size: 25 MB 网页链接查看全文
快而精医药(QGEN)03-11 18:05
$快而精医药(QGEN)$ IRANNOTICE Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)). Accession Number: 0001015820-24-000023 Act: 34 Size: 101 KB 网页链接查看全文
快而精医药(QGEN)03-11 18:05
$快而精医药(QGEN)$ 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)] Accession Number: 0001015820-24-000022 Act: 34 Size: 38 MB 网页链接查看全文
快而精医药(QGEN)02-08 22:55
$快而精医药(QGEN)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001015820-24-000008 Act: 34 Size: 618 KB 网页链接查看全文
快而精医药(QGEN)02-10 00:55
$快而精医药(QGEN)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000912938-24-000212 Act: 34 Size: 17 KB 网页链接查看全文
快而精医药(QGEN)01-24 05:15
$快而精医药(QGEN)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001086364-24-001668 Act: 34 Size: 13 KB 网页链接查看全文
快而精医药(QGEN)01-23 19:05
$快而精医药(QGEN)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001015820-24-000005 Act: 34 Size: 155 KB 网页链接查看全文
快而精医药(QGEN)01-08 23:05
$快而精医药(QGEN)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001015820-24-000002 Act: 34 Size: 151 KB 网页链接查看全文
快而精医药(QGEN)2023-12-07 01:45
$快而精医药(QGEN)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000912938-23-000512 Act: 34 Size: 17 KB 网页链接查看全文
快而精医药(QGEN)2023-11-01 18:15
$快而精医药(QGEN)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001015820-23-000053 Act: 34 Size: 1 MB 网页链接查看全文
智通财经APP获悉，快而精医药(QGEN.US)正在评估出售其生物信息学业务的少数股权，该业务的估值可能超过10亿美元。据报道，这家诊断公司正在与顾问合作，为该业务寻找潜在买家。快而精医药尚未做出最终决定。 据报道，此次股权出售预计将... 网页链接
智通财经APP获悉，快而精医药(QGEN.US)周一表示，该公司已完成对私人持股的基因测序公司Verogen的收购，以加强该公司未来在人类身份识别和取证领域的领先地位。快而精医药将支付1.5亿美元的现金以完成收购。 快而精医药总部位于荷兰，提... 网页链接
智通财经APP获悉，美国食品和药物管理局(FDA)批准快而精医药(QGEN.US)的therascreen KRAS RGQ PCR 试剂盒作为Mirati Therapeutics(MRTX.US)癌症药物Krazati的伴随诊断产品。Krazati最近被FDA批准用于治疗非小细胞肺癌(NSCLC)患者。 据了... 网页链接
$快而精医药(QGEN)$ 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)] Accession Number: 0001015820-24-000022 Act: 34 Size: 38 MB 网页链接
$快而精医药(QGEN)$ IRANNOTICE Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)). Accession Number: 0001015820-24-000023 Act: 34 Size: 101 KB 网页链接
$快而精医药(QGEN)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000912938-24-000212 Act: 34 Size: 17 KB 网页链接
$快而精医药(QGEN)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001015820-24-000008 Act: 34 Size: 618 KB 网页链接
$快而精医药(QGEN)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001086364-24-001668 Act: 34 Size: 13 KB 网页链接
$快而精医药(QGEN)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001015820-24-000005 Act: 34 Size: 155 KB 网页链接
$快而精医药(QGEN)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001015820-24-000002 Act: 34 Size: 151 KB 网页链接
$快而精医药(QGEN)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000912938-23-000512 Act: 34 Size: 17 KB 网页链接
$快而精医药(QGEN)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001015820-23-000053 Act: 34 Size: 1 MB 网页链接
$快而精医药(QGEN)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001015820-23-000050 Act: 34 Size: 530 KB 网页链接